IL2RA and primary cutaneous T-cell non-Hodgkin lymphoma: After being withdrawn from the market in 2014, a re-engineered formulation of denileukin diftitox with enhanced purity and bioactivity (denileukin diftitox-cxdl) received FDA approval in August 2024 for cutaneous T cell lymphoma (CTCL) expressing IL-2Ra (CD25).